ARTICLE | Management Tracks
Remy Sukhija leaving Madrigal as CCO
Plus: Editas hires Caren Deardorf as chief commercial and strategy officer, and updates from ProFound and hC
September 25, 2023 11:48 PM UTC
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said Remy Sukhija is departing as chief commercial officer to pursue other opportunities. His departure comes two weeks after FDA granted Madrigal’s resmetirom priority review for non-alcoholic steatohepatitis with liver fibrosis; the PDUFA date is March 14. Sukhija joined the company in April 2020 from Otsuka Pharmaceutical Co. Ltd., where he was SVP, U.S. commercial.
Genome editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Caren Deardorf as its first chief commercial and strategy officer. Deardorf, a 15-year veteran of Biogen Inc. (NASDAQ:BIIB), was CCO at Magenta Therapeutics Inc. and Ohana Biosciences. ...